Unicycive Therapeutics (UNCY) Competitors $3.87 -0.22 (-5.38%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.90 +0.03 (+0.90%) As of 09/12/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock UNCY vs. DMAC, SCPH, CTNM, FDMT, CAPR, FHTX, LFCR, TVRD, NMRA, and GALTShould you be buying Unicycive Therapeutics stock or one of its competitors? The main competitors of Unicycive Therapeutics include DiaMedica Therapeutics (DMAC), scPharmaceuticals (SCPH), Contineum Therapeutics (CTNM), 4D Molecular Therapeutics (FDMT), Capricor Therapeutics (CAPR), Foghorn Therapeutics (FHTX), Lifecore Biomedical (LFCR), Tvardi Therapeutics (TVRD), Neumora Therapeutics (NMRA), and Galectin Therapeutics (GALT). These companies are all part of the "pharmaceutical products" industry. Unicycive Therapeutics vs. Its Competitors DiaMedica Therapeutics scPharmaceuticals Contineum Therapeutics 4D Molecular Therapeutics Capricor Therapeutics Foghorn Therapeutics Lifecore Biomedical Tvardi Therapeutics Neumora Therapeutics Galectin Therapeutics Unicycive Therapeutics (NASDAQ:UNCY) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings. Which has more volatility and risk, UNCY or DMAC? Unicycive Therapeutics has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.4, suggesting that its share price is 40% more volatile than the S&P 500. Does the media prefer UNCY or DMAC? In the previous week, Unicycive Therapeutics had 20 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 24 mentions for Unicycive Therapeutics and 4 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 0.93 beat Unicycive Therapeutics' score of -0.10 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 16 Neutral mention(s) 3 Negative mention(s) 4 Very Negative mention(s) Neutral DiaMedica Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, UNCY or DMAC? DiaMedica Therapeutics has lower revenue, but higher earnings than Unicycive Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUnicycive Therapeutics$680K100.51-$36.73M-$4.12-0.94DiaMedica TherapeuticsN/AN/A-$24.44M-$0.69-10.28 Is UNCY or DMAC more profitable? DiaMedica Therapeutics' return on equity of -78.99% beat Unicycive Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Unicycive TherapeuticsN/A -243.13% -119.46% DiaMedica Therapeutics N/A -78.99%-69.94% Do analysts rate UNCY or DMAC? Unicycive Therapeutics presently has a consensus price target of $60.00, suggesting a potential upside of 1,450.39%. DiaMedica Therapeutics has a consensus price target of $12.33, suggesting a potential upside of 73.95%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Unicycive Therapeutics is more favorable than DiaMedica Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Unicycive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of UNCY or DMAC? 40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 10.7% of Unicycive Therapeutics shares are held by company insiders. Comparatively, 7.3% of DiaMedica Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryUnicycive Therapeutics beats DiaMedica Therapeutics on 9 of the 15 factors compared between the two stocks. Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UNCY vs. The Competition Export to ExcelMetricUnicycive TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$72.24M$2.59B$5.87B$10.13BDividend YieldN/A56.52%5.68%4.60%P/E Ratio-0.9423.5374.5225.93Price / Sales100.51523.61517.44183.79Price / CashN/A171.1637.5660.44Price / Book5.385.3712.166.29Net Income-$36.73M$32.95M$3.28B$270.77M7 Day Performance-11.24%1.28%0.87%3.88%1 Month Performance-12.24%6.09%4.96%4.88%1 Year Performance-2.03%-2.15%60.75%26.01% Unicycive Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UNCYUnicycive Therapeutics1.9644 of 5 stars$3.87-5.4%$60.00+1,450.4%+1.8%$72.24M$680K-0.949High Trading VolumeDMACDiaMedica Therapeutics2.2293 of 5 stars$5.71-2.7%$12.33+116.0%+65.3%$295.14MN/A-8.2820Analyst UpgradeSCPHscPharmaceuticals4.5104 of 5 stars$5.50-0.2%$12.00+118.2%+6.0%$293.14M$36.33M-3.0430Positive NewsShort Interest ↓High Trading VolumeCTNMContineum Therapeutics2.6789 of 5 stars$10.45+4.0%$22.75+117.7%-31.6%$293.04M$50M-4.7531Short Interest ↑FDMT4D Molecular Therapeutics2.6667 of 5 stars$6.16-0.3%$30.40+393.5%-57.2%$287.69M$40K-1.75120News CoveragePositive NewsCAPRCapricor Therapeutics2.2106 of 5 stars$6.28+0.3%$22.56+259.2%+52.2%$287.10M$22.27M-3.83101Analyst ForecastFHTXFoghorn Therapeutics2.7484 of 5 stars$5.06+1.0%$10.67+110.8%-41.6%$286.04M$22.60M-4.25120Positive NewsLFCRLifecore Biomedical1.143 of 5 stars$7.61-0.1%$8.00+5.1%+46.9%$284.67M$128.87M-5.81690Positive NewsTVRDTvardi Therapeutics2.7188 of 5 stars$29.92-1.2%$64.25+114.7%N/A$280.57M$7.14M0.0080Positive NewsNMRANeumora Therapeutics2.9055 of 5 stars$1.73-1.7%$7.14+312.9%-86.3%$280.17MN/A-1.10108News CoveragePositive NewsGALTGalectin Therapeutics1.3312 of 5 stars$4.28+0.7%$6.00+40.2%+98.2%$274.18MN/A-6.699Positive NewsGap Up Related Companies and Tools Related Companies DiaMedica Therapeutics Alternatives scPharmaceuticals Alternatives Contineum Therapeutics Alternatives 4D Molecular Therapeutics Alternatives Capricor Therapeutics Alternatives Foghorn Therapeutics Alternatives Lifecore Biomedical Alternatives Tvardi Therapeutics Alternatives Neumora Therapeutics Alternatives Galectin Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UNCY) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free UNCY Stock Alerts